Literature DB >> 15106096

Population immunity to measles in the United States, 1999.

Sonja S Hutchins1, William J Bellini, Victor Coronado, Ruth Jiles, Karen Wooten, Adeline Deladisma.   

Abstract

To estimate population immunity, we examined measles immunity among residents of the United States in 1999 from serological and vaccine coverage surveys. For persons aged >or=20 years, serological data from the third National Health and Nutrition Examination Survey (1988-1994) were used. For persons <20 years of age, immunity was estimated from results of the National Immunization Survey (1994-1998), state surveys of school entrants (1990-2000), and vaccine coverage surveys of adolescents (1997). To estimate immunity from vaccine coverage data, 95% vaccine efficacy was used for recipients of a single dose at >or=12 years of age and 99% vaccine efficacy was used for those with failure of a first dose who were revaccinated. Overall, calculated population immunity was found to be 93%. Although there was not much variation in immunity by region and state, in some large urban centers immunity among preschool-aged children was as low as 86%. Overall, geographic- and age-specific estimates of a high population immunity support the epidemiological evidence that measles disease is no longer endemic in the United States.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106096     DOI: 10.1086/377713

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Humoral responses to independent vaccinations are correlated in healthy boosted adults.

Authors:  Lori Garman; Amanda J Vineyard; Sherry R Crowe; John B Harley; Christina E Spooner; Limone C Collins; Michael R Nelson; Renata J M Engler; Judith A James
Journal:  Vaccine       Date:  2014-08-17       Impact factor: 3.641

2.  MMR vaccination status of children exempted from school-entry immunization mandates.

Authors:  Alison M Buttenheim; Karthik Sethuraman; Saad B Omer; Alexandra L Hanlon; Michael Z Levy; Daniel Salmon
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

3.  Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides.

Authors:  C Mathieu; D Huey; E Jurgens; J C Welsch; I DeVito; A Talekar; B Horvat; S Niewiesk; A Moscona; M Porotto
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

4.  Exposure of California kindergartners to students with personal belief exemptions from mandated school entry vaccinations.

Authors:  Alison Buttenheim; Malia Jones; Yelena Baras
Journal:  Am J Public Health       Date:  2012-06-14       Impact factor: 9.308

Review 5.  A global perspective of vaccination of healthcare personnel against measles: systematic review.

Authors:  Amy Parker Fiebelkorn; Jane F Seward; Walter A Orenstein
Journal:  Vaccine       Date:  2013-11-24       Impact factor: 3.641

6.  Immunity to polio, measles and rubella in women of child-bearing age and estimated congenital rubella syndrome incidence, Cambodia, 2012.

Authors:  B Mao; K Chheng; K Wannemuehler; E Vynnycky; S Buth; S C Soeung; S Reef; W Weldon; L Quick; C J Gregory
Journal:  Epidemiol Infect       Date:  2014-11-06       Impact factor: 4.434

7.  Measles fusion machinery is dysregulated in neuropathogenic variants.

Authors:  Eric M Jurgens; Cyrille Mathieu; Laura M Palermo; Diana Hardie; Branka Horvat; Anne Moscona; Matteo Porotto
Journal:  mBio       Date:  2015-02-10       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.